Kawasaki disease (KD) is an acute, self-limited vasculitis of medium-sized arteries that leads to coronary artery aneurysms in approximately 25% of untreated patients. Timely treatment with intravenous immunoglobulin (IVIG) has decreased this risk to 3% to 5%. Incomplete KD is a risk factor for delayed diagnosis and treatment, thus increasing the risk for coronary artery abnormalities (CAAs). The American Heart Association (AHA) guideline provides a diagnostic algorithm for suspected cases of incomplete KD, which has retrospectively been shown to hasten treatment.1,2 There remains a subset of children, particularly infants younger than 6 months and adolescents, in whom the diagnosis is exceedingly challenging. Once the diagnosis is made, the treatment of complete and incomplete KD is identical. Intravenous immunoglobulin and acetylsalicylic acid are the hallmarks of therapy. The use of adjunctive agents and strategies for treatment of IVIG-resistant disease remains controversial.1
Sosa T, Brower L, Divanovic A. Diagnosis and Management of Kawasaki Disease. JAMA Pediatr. 2019;173(3):278–279. doi:10.1001/jamapediatrics.2018.3307
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: